Botanix Pharmaceuticals (BOT)
Botanix Pharmaceuticals Ltd. engages in the development of next generation therapeutics for the treatment of skin diseases. It focuses on the treatment of patients battling with acne, psoriasis, and atoptic dermatitis. The company also develops pharmaceutical ingredient known as cannabidol, which seeks to treat epilepsy, pain, arthritis, and schizophrenia. Botanix Pharmaceuticals was founded by Roger New and Glen Travers in December 2002 and is headquartered in Northbridge, Australia.
|Market Price at 15-12-2017||$0.06|
|Price to Earnings Ratio||-3.92|
|Market Capitalisation||$32.04 (million)|
|Return on Equity (ROE)||-87.5%|